Increased total cytokeratin-18 serum and urine levels in chronic kidney disease

Clinica Chimica Acta

Volumn 412, Issue 9-10, 2011, Pages 713-717

  Roth, Georg A ^a   Lebherz Eichinger, Diana ^a   Ankersmit, Hendrik Jan ^a   Hacker, Stefan ^a   Hetz, Hubert ^a   Vukovich, Thomas ^a   Perne, Andrea ^a   Reiter, Thomas ^a   Farr, Alexander ^a   Hörl, Walter H ^a   Haas, Martin ^a   Krenn, Claus G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Cell death; Chronic kidney disease; Cytokeratin 18; Necrosis

Indexed keywords

ALBUMIN; CYTOKERATIN 18;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; CASPASES; FEMALE; HUMANS; KERATIN-18; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ROC CURVE; YOUNG ADULT;

EID: 79951727128     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.12.030     Document Type: Article

References (26)

1. Collins A.J., Kasiske B., Herzog C., et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005, 45(A5-7):S1-S280.
2. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-147.
3. Meyer T.W., Hostetter T.H. Uremia. N Engl J Med 2007, 357:1316-1325.
4. Cohen G., Rudnicki M., Horl W.H. Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. Kidney Int Suppl 2001, 78:S48-S52.
5. Ankersmit H.J., Deicher R., Moser B., et al. Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol 2001, 125:142-148.
6. Vanholder R., Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 1993, 3:1541-1554.
7. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006, 70:26-33.
8. Moser B., Roth G., Brunner M., et al. Aberrant T cell activation and heightened apoptotic turnover in end-stage renal failure patients: a comparative evaluation between non-dialysis, haemodialysis, and peritoneal dialysis. Biochem Biophys Res Commun 2003, 308:581-585.
9. Cohen G., Rudnicki M., Walter F., Niwa T., Horl W.H. Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. J Am Soc Nephrol 2001, 12:1264-1271.
10. Raj D.S., Shah H., Shah V.O., et al. Markers of inflammation, proteolysis, and apoptosis in ESRD. Am J Kidney Dis 2003, 42:1212-1220.
11. Kumar D., Robertson S., Burns K.D. Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem 2004, 259:67-70.
12. Truong L.D., Shen S.S., Park M.H., Krishnan B. Diagnosing nonneoplastic lesions in nephrectomy specimens. Arch Pathol Lab Med 2009, 133:189-200.
13. Leers M.P., Kolgen W., Bjorklund V., et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999, 187:567-572.
14. Roth G.A., Krenn C., Brunner M., et al. Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope M30 in critically ill patients. Shock 2004, 22:218-220.
15. Adlbrecht C., Hoetzenecker K., Posch M., et al. Elevated levels of interleukin-1beta-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction. Eur J Clin Invest 2007, 37:372-380.
16. Schumann R. Intraoperative resource utilization in anesthesia for liver transplantation in the United States: a survey. Anesth Analg 2003, 97:21-28. table of contents.
17. Krysko D.V., Vanden Berghe T., D'Herde K., Vandenabeele P. Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods 2008, 44:205-221.
18. Bergsbaken T., Fink S.L., Cookson B.T. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009, 7:99-109.
19. Chu P.G., Weiss L.M. Keratin expression in human tissues and neoplasms. Histopathology 2002, 40:403-439.
20. Hagg M., Biven K., Ueno T., et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002, 20:253-259.
21. Kramer G., Erdal H., Mertens H.J., et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004, 64:1751-1756.
22. Bantel H., Ruck P., Gregor M., Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001, 80:230-239.
23. Wieckowska A., Zein N.N., Yerian L.M., Lopez A.R., McCullough A.J., Feldstein A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
24. Morcos M., Sayed A.A., Bierhaus A., et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002, 51:3532-3544.
25. Hofer S., Brenner T., Bopp C., et al. Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction. Crit Care 2009, 13:R93.
26. Leers M.P., Bjorklund V., Bjorklund B., Jornvall H., Nap M. An immunohistochemical study of the clearance of apoptotic cellular fragments. Cell Mol Life Sci 2002, 59:1358-1365.